Chase Doyle | Authors

Articles

KRISTINE Trial Demonstrates TCH+P Still Best Choice for HER2+ Breast Cancer

July 21, 2016

Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response (pCR) rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P) versus trastuzumab emtansine (T-DM1) plus pertuzumab (T-DM1+P).

Comparing Combination Treatments in HER2-Positive Early Breast Cancer

June 10, 2016

In patients with HER2-positive early breast cancer, data from a phase III trial has shown a significantly higher pathological complete response (pCR) rate with neoadjuvant docetaxel plus carboplatin plus trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.

Joint Trial Analysis Confirms Benefit of Anthracyclines in High-Risk Breast Cancer

June 06, 2016

A joint analysis of the "ABC" trials comparing anthracycline versus non-anthracycline treatment in patients with high-risk, HER2-negative breast cancer has failed to demonstrate non-inferiority of the non-anthracycline regimen.

Study Demonstrates Tolerability of Obinutuzumab Combo in Patients with Previously Untreated CLL

December 10, 2015

A combination of venetoclax and obinutuzumab, followed by additional cycles of venetoclax, has shown tolerability in elderly patients with previously untreated chronic lymphocytic leukemia with comorbidities, data from the CLL14 trial (BO25323) shows.